
FULC Stock Forecast & Price Target
FULC Analyst Ratings
Bulls say
Fulcrum Therapeutics is facing various risks, such as unexpected clinical or regulatory issues, potential commercial setbacks, and dilutive financing, which could negatively impact the stock. However, there is potential for upside from strategic alternative plans or regulatory flexibility. The company recently discontinued its product candidate, pociredir, due to concerns over its class of drugs, but still has a strong cash position of $333 million. Due to these uncertainties, the rating for the stock has been downgraded to Underweight and the price target has been reduced from $23 to $3, removing all value for pociredir in the projected mid-2027.
Bears say
Fulcrum Therapeutics is in a dire situation after the FDA discontinued their flagship product Pociredir's development for the treatment of sickle cell disease. The FDA's concerns about the potential risks of the drug's class, compounded by recent data from a similar drug, have led to a halt in the company's development plans. This has led to a significant loss of potential value for Fulcrum and raises concerns about their ability to secure additional capital, making it prudent for investors to stay away until further updates are announced.
This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FULC Analyst Forecast & Price Prediction
Start investing in FULC
Order type
Buy in
Order amount
Est. shares
0 shares